-
- Xu Zhang
- Jiangsu Key Laboratory of Medical Science and Laboratory Medicine School of Medicine Jiangsu University Zhenjiang 212013 P. R. China
-
- Hongbo Zhang
- Pharmaceutical Sciences Laboratory and Turku Bioscience Centre Åbo Akademi University Turku 20520 Finland
-
- Jianmei Gu
- Department of Clinical Laboratory Medicine Nantong Tumor Hospital Nantong 226361 P. R. China
-
- Jiayin Zhang
- Jiangsu Key Laboratory of Medical Science and Laboratory Medicine School of Medicine Jiangsu University Zhenjiang 212013 P. R. China
-
- Hui Shi
- Jiangsu Key Laboratory of Medical Science and Laboratory Medicine School of Medicine Jiangsu University Zhenjiang 212013 P. R. China
-
- Hui Qian
- Jiangsu Key Laboratory of Medical Science and Laboratory Medicine School of Medicine Jiangsu University Zhenjiang 212013 P. R. China
-
- Dongqing Wang
- Department of Radiology Affiliated Hospital of Jiangsu University Jiangsu University Zhenjiang 212001 P. R. China
-
- Wenrong Xu
- Jiangsu Key Laboratory of Medical Science and Laboratory Medicine School of Medicine Jiangsu University Zhenjiang 212013 P. R. China
-
- Jianming Pan
- School of Chemistry and Chemical Engineering Jiangsu University Zhenjiang 212013 P. R. China
-
- Hélder A. Santos
- Drug Research Program Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki Helsinki FI‐00014 Finland
説明
<jats:title>Abstract</jats:title><jats:p>Extracellular vesicles (EVs) have emerged as a novel cell‐free strategy for the treatment of many diseases including cancer. As a result of their natural properties to mediate cell‐to‐cell communication and their high physiochemical stability and biocompatibility, EVs are considered as excellent delivery vehicles for a variety of therapeutic agents such as nucleic acids and proteins, drugs, and nanomaterials. Increasing studies have shown that EVs can be modified, engineered, or designed to improve their efficiency, specificity, and safety for cancer therapy. Herein, a comprehensive overview of the recent advances in the strategies and methodologies of engineering EVs for scalable production and improved cargo‐loading and tumor‐targeting is provided. Additionally, the potential applications of engineered EVs in cancer therapy are discussed by presenting prominent examples, and the opportunities and challenges for translating engineered EVs into clinical practice are evaluated.</jats:p>
収録刊行物
-
- Advanced Materials
-
Advanced Materials 33 (14), e2005709-, 2021-02-28
Wiley
